Bexarotene topical

Drug Profile

Bexarotene topical

Alternative Names: Bexarotene gel; LGD 1069 topical; Targretin gel; Targretyn gel; Tarrexin gel

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ligand Pharmaceuticals
  • Developer Eisai Co Ltd
  • Class Antineoplastics; Benzoic acids; Naphthalenes; Retinoids; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor agonists; Protein synthesis inhibitors; Retinoic acid receptor agonists; Retinoid X receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cutaneous T cell lymphoma
  • Discontinued Actinic keratosis; Alopecia areata; Atopic dermatitis; Basal cell cancer; Kaposi's sarcoma; Mycosis fungoides; Psoriasis

Most Recent Events

  • 22 Jun 2017 Bexarotene licensed to Ewopharma for commercialisation in Hungary and Poland
  • 29 Apr 2016 Biomarkers information updated
  • 24 Apr 2015 Preregistration for Cutaneous T-cell lymphoma in Mexico (Topical) before April 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top